Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
RN Amaria, AM Menzies, EM Burton… - The Lancet …, 2019 - thelancet.com
Advances in the treatment of metastatic melanoma have improved responses and survival.
However, many patients continue to experience resistance or toxicity to treatment …
However, many patients continue to experience resistance or toxicity to treatment …
[HTML][HTML] Clinical review: Serious adverse events associated with the use of rituximab-a critical care perspective
PM Kasi, HA Tawbi, CV Oddis, HS Kulkarni - Critical Care, 2012 - Springer
The advent of biologic agents has provided a more specific and targeted approach to the
treatment of various hematological malignancies and other autoimmune disorders. Such …
treatment of various hematological malignancies and other autoimmune disorders. Such …
Development of immunotherapy combination strategies in cancer
Harnessing the immune system to treat cancer through inhibitors of CTLA4 and PD-L1 has
revolutionized the landscape of cancer. Rational combination strategies aim to enhance the …
revolutionized the landscape of cancer. Rational combination strategies aim to enhance the …
[HTML][HTML] Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
HA Tawbi, D Schadendorf, EJ Lipson… - … England Journal of …, 2022 - Mass Medical Soc
Background Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
CN Spencer, JL McQuade, V Gopalakrishnan… - Science, 2021 - science.org
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in
cancer, but the effect of diet and supplements on this interaction is not well studied. We …
cancer, but the effect of diet and supplements on this interaction is not well studied. We …
B cells and tertiary lymphoid structures promote immunotherapy response
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …
B cells are associated with survival and immunotherapy response in sarcoma
F Petitprez, A de Reyniès, EZ Keung, TWW Chen… - Nature, 2020 - nature.com
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …
histological subtypes,. The clinical presentation of patients with different subtypes is often …
[HTML][HTML] Combined nivolumab and ipilimumab in melanoma metastatic to the brain
HA Tawbi, PA Forsyth, A Algazi, O Hamid… - … England Journal of …, 2018 - Mass Medical Soc
Background Brain metastases are a common cause of disabling neurologic complications
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
HA Tawbi, M Burgess, V Bolejack, BA Van Tine… - The Lancet …, 2017 - thelancet.com
Background Patients with advanced sarcomas have a poor prognosis and few treatment
options that improve overall survival. Chemotherapy and targeted therapies offer short-lived …
options that improve overall survival. Chemotherapy and targeted therapies offer short-lived …
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …